Alnylam Pharmace. buy tamam
Start price
20.09.17
/
50%
€87.81
Target price
20.09.17
€76.67
Performance (%)
7.87%
End price
20.09.17
€94.72
Summary
This prediction ended on 20.09.17 with a price of €94.72. The BUY prediction by tamam finished with a performance of 7.87%. tamam has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -1.538% | -1.538% | 47.276% | 45.558% |
| iShares Core DAX® | 3.054% | -1.396% | 15.789% | 12.675% |
| iShares Nasdaq 100 | 4.389% | -5.391% | 29.906% | 39.325% |
| iShares Nikkei 225® | 5.386% | -3.105% | 16.065% | 8.150% |
| iShares S&P 500 | 2.955% | -3.011% | 25.903% | 37.650% |
Comments by tamam for this prediction
In the thread Alnylam Pharmace. diskutieren
tamam stimmt der Buy-Einschätzung von melinda zu
tamam stimmt am 20.09.2017 der Buy-Einschätzung von melinda mit dem Kursziel 85$ zu.
Überschrift: pharma